DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Grows Stock Position in BioNTech SE (NASDAQ:BNTX)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in BioNTech SE (NASDAQ:BNTX - Free Report) by 632.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 501,897 shares of the company's stock after buying an additional 433,388 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main owned 0.21% of BioNTech worth $57,191,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Crestline Management LP bought a new position in BioNTech in the 4th quarter worth about $943,000. Braidwell LP lifted its holdings in shares of BioNTech by 25.1% during the 4th quarter. Braidwell LP now owns 309,865 shares of the company's stock valued at $35,309,000 after buying an additional 62,115 shares during the period. Bridgefront Capital LLC purchased a new position in BioNTech during the fourth quarter valued at $284,000. Baker BROS. Advisors LP purchased a new position in shares of BioNTech in the fourth quarter valued at about $5,131,000. Finally, Baird Financial Group Inc. lifted its position in shares of BioNTech by 14.2% in the fourth quarter. Baird Financial Group Inc. now owns 18,589 shares of the company's stock worth $2,118,000 after buying an additional 2,307 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on BNTX shares. HC Wainwright reiterated a "buy" rating and set a $134.00 price objective (down previously from $145.00) on shares of BioNTech in a report on Wednesday. Citigroup reiterated a "buy" rating and issued a $140.00 target price (down from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. BMO Capital Markets raised their price target on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. Morgan Stanley cut their target price on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating for the company in a report on Tuesday, May 6th. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $171.44 target price on shares of BioNTech in a report on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, BioNTech currently has an average rating of "Moderate Buy" and a consensus target price of $142.08.

BioNTech Trading Down 0.9%

NASDAQ BNTX traded down $0.85 during trading hours on Wednesday, hitting $93.65. 264,446 shares of the company's stock were exchanged, compared to its average volume of 922,445. The stock has a 50-day simple moving average of $98.12 and a 200 day simple moving average of $109.29. The firm has a market cap of $22.47 billion, a price-to-earnings ratio of -44.60 and a beta of 1.35. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same period in the prior year, the business posted $1.90 earnings per share. The company's revenue was down 19.5% on a year-over-year basis. On average, equities analysts forecast that BioNTech SE will post -3.88 EPS for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.